Providence para unirse a los líderes en medicina neuroendocrina en la conferencia educativa regional

Providence Cancer Institute to cohost Oregon neuroendocrine tumor conference

Providence Cancer Institute, along with Oregon Health & Science University and the North American Neuroendocrine Tumor Society (NANETS), will host a comprehensive medical educational conference for health professionals interested in the treatment of patients with neuroendocrine tumors. The event will be held Saturday, June 25, at the Bidwell Marriot in Portland, Oregon.

Neuroendocrine tumors (NETs) — sometimes called carcinoids — are cancers that start in the endocrine cells found throughout the body. Neuroendocrine cells produce hormones, which help the body control many functions from breathing to digestion. NETs form when these cells mutate and multiply, forming a tumor, and can occur anywhere in the body and are most common in the small and large intestine, pancreas, appendix and lung.

During this conference, led by course co-director Dr. Hagen Kennecke, Providence medical director of Gastrointestinal (GI) Oncology, attendees will learn about all aspects of specialized NET care including tips on how to treat these complex patients. Topics will include:

  • Overview of NETs
  • Surgical Treatment of NETs
  • Medical Management of NETs
  • Hormonal Management and Symptom Control
  • Carcinoid Heart Disease
  • Pheochromocytoma & Paraganglioma
  • Case Presentations

Participants will have the opportunity to hear from a variety of specialists in oncology, gastroenterology, pulmonology, surgery, and radiology. Continuing medical education (CME) and continuing nursing education (CNE) is available.

Full conference details and registration information can be found at https://nanets.net/portland.

About the Providence presenters

We are thrilled to have physicians from Providence Cancer Institute of Oregon among this year's presenters:

Hagen Kennecke, M.D. is a medical oncologist and medical director of Gastrointestinal (GI) Oncology at Providence Cancer Institute in Portland, Oregon. He works passionately to improve the treatment, education and outcomes of those affected by colorectal and neuroendocrine cancers. He is the current chair of the United States National Cancer Institute (NCI) Rectal-Anal Cancer Task Force and the SWOG Recto-Anal Cancer Subcommittee.

Michele Babicky, M.D. is medical director of the Providence Hepatobiliary and Pancreatic Cancer Program and is a surgical oncologist with The Oregon Clinic. Dr. Babicky became a surgical oncologist so she could use her knowledge of medicine and science to help patients at a critical and vulnerable time. She completed her general surgery residency at the University of California San Diego. She then spent two years as a Complex General Surgical Oncology fellow at Memorial Sloan-Kettering Cancer Center in New York City. Dr. Babicky has a strong background in basic science research, with an emphasis on signal transduction pathways and immunology in pancreatic and bile duct cancers.

Maria Ximena Traa Keily, M,D., MPH is a Providence-affiliated colon and rectal surgeon with The Oregon Clinic. Dr. Kiely received her Master of Public Health degree with a concentration in Quantitative Methods from Harvard. She joined the colorectal field because she felt that there was a need for women surgeons in the specialty, especially given that women often leave anorectal and pelvic floor issues untreated due to concerns about embarrassing exams and discussions.

Michael Layoun, M.D. has a Bachelor of Science in biochemistry and biophysics at Oregon State University and completed his medical training at Oregon Health & Science University (OHSU). After a three-year residency at University of California, Los Angeles, he returned to Portland to complete his cardiovascular medicine fellowship at OHSU, where he also served as chief fellow during his final year of training. Dr. Layoun also holds specialized training in vascular medicine, nuclear cardiology and cardiac computed tomography. 

About NET treatment at Providence

All patients with a new diagnosis of a NET are presented at the Providence tumor boards. There, a team of experts talk about a patient’s diagnosis and review pathology and imaging to recommend the best treatments.

Personalized treatment plans may include surgery, chemotherapy, peptide receptor radioparticle therapy (PRRT), liver-directed therapy, radiation therapy and other treatments, including clinical trials. 

To learn more, visit Providence Neuroendocrine Tumor Treatment.

Related news

Meet Dr. Hagen Kennecke: Following his passion to advance cancer care

11/28/2022
As much a cancer diagnosis can ever be, Jean’s was well-timed. Providence St. Peter Hospital had just launched a new program dedicated specifically to the early detection.
11/30/2022
Preventing and detecting disease early can significantly improve patient health. Learn more about how Providence is using population genomics to reach that goal.
11/23/2022
Providence Cancer Institute to hold two virtual events on the benefits of integrative medicine for patients.
11/7/2022
Providence Cancer Institute one of only a few sites worldwide offering two new clinical trials for solid tumors and lung cancer.
Powered by Translations.com GlobalLink OneLink SoftwarePowered By OneLink